These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 15356967)

  • 1. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.
    Braun J; Asmus HG; Holzer H; Brunkhorst R; Krause R; Schulz W; Neumayer HH; Raggi P; Bommer J
    Clin Nephrol; 2004 Aug; 62(2):104-15. PubMed ID: 15356967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density.
    Asmus HG; Braun J; Krause R; Brunkhorst R; Holzer H; Schulz W; Neumayer HH; Raggi P; Bommer J
    Nephrol Dial Transplant; 2005 Aug; 20(8):1653-61. PubMed ID: 15930018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H; Koiwa F; Shishido K; Kinugasa E
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
    Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
    Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
    Chertow GM; Burke SK; Raggi P;
    Kidney Int; 2002 Jul; 62(1):245-52. PubMed ID: 12081584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.
    Di Iorio B; Molony D; Bell C; Cucciniello E; Bellizzi V; Russo D; Bellasi A;
    Am J Kidney Dis; 2013 Oct; 62(4):771-8. PubMed ID: 23684755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.
    Huybrechts KF; Caro JJ; Wilson DA; O'Brien JA
    Value Health; 2005; 8(5):549-61. PubMed ID: 16176493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
    Nolan CR; Qunibi WY
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
    Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
    Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients.
    Chertow GM; Raggi P; McCarthy JT; Schulman G; Silberzweig J; Kuhlik A; Goodman WG; Boulay A; Burke SK; Toto RD
    Am J Nephrol; 2003; 23(5):307-14. PubMed ID: 12915774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer.
    Raggi P; Bommer J; Chertow GM
    J Heart Valve Dis; 2004 Jan; 13(1):134-41. PubMed ID: 14765851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
    J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
    Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium-containing phosphate binder use associated with accelerated atherosclerotic coronary calcification.
    Paret CL
    J Ren Nutr; 2003 Oct; 13(4):288-94. PubMed ID: 14566766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
    Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
    Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.